Navigation Links
VolitionRX Limited Issues 525,000 Shares to ValiRx; Final Requirement of Share Purchase Agreement
Date:12/9/2011

SINGAPORE, Dec. 9, 2011 /PRNewswire/ -- VolitionRX Limited (VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is pleased to announce that it will issue US$1,110,000 worth of shares of its common stock to AIM-listed company, ValiRx PLC.  The share issuance is the final requirement of the Share Purchase Agreement dated 22 September 2010 (as amended on 9 June 2011) between ValiRx and Singapore Volition Pte Limited, a subsidiary of VolitionRX.

Volition will issue 525,000 restricted shares of common stock to ValiRx. Of that number of shares, 14,189 shares will be issued directly to Chroma Therapeutics Limited of Abingdon, Oxfordshire, UK, as payment for the direct licensing of Chroma Therapeutics's patent "Detection Of Histone Modifications In Cell-Free Nucleosomes" to Singapore Volition.

Cameron Reynolds, CEO of VolitionRX, said, "We're grateful to ValiRx for their advice and support over the last 15 months, and are therefore delighted to make this final payment of shares to ValiRx. We're also happy to be issuing shares as royalty to Chroma Therapeutics, whose patent forms a significant part of our technology portfolio."

About VolitionRX
VolitionRX is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.

VolitionRX is managed by a well-respected team with extensive experience in diagnostics and commercialization. VolitionRX's development activities are currently centered in Belgium and will be augmented by commercialization work in Singapore with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

VolitionRX is quoted on the OTC Bulletin Board in the United States of America, under the symbol VNRX.OB.

Forward-Looking Statements: Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.

 


'/>"/>
SOURCE VolitionRX Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures
2. VolitionRX Limited Issues Update Letter to Shareholders
3. Ansell Limited Acquires a Minority Share in Yulex Corporation
4. RSNA 2011: Ziehm Imaging Presents Innovative Mobile C-Arms for Virtually Unlimited Imaging
5. Vista Partners Updates Coverage on Cellmid Limited; Raises Target Price to AUD $0.12
6. Navigating Cancer and Unlimited Systems Partner to Provide Cancer Clinics With IT Interoperability to Attain HITECH Act Incentives
7. Express Scripts HealthBridge Pharma & Biotech to Provide Exclusive Specialty Pharmacy Services and Limited Distribution Services for Solesta®
8. BD to Increase Access to Vital Cervical Cancer Screening in Resource-Limited Settings Through Commitment to Pink Ribbon Red Ribbon Initiative®
9. Panacea Global, Inc. Signs Multi-year Contract Valued at Minimum $8.75 Million for Cancer Detection System with Palmverse Limited
10. Ansell Limited Acquires Sandel Medical Industries LLC, an Innovator in Surgical Safety Solutions
11. Masimo Initiates Limited Market Release of E1, Single-Patient-Use Ear Sensor for Pulse Oximetry Monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ALEXANDRIA, Va. , Feb. 12, 2016  This ... & Specialty Pharmacy (JMCP) takes an in-depth look ... the recent spike in prescription drug spending, which has ... JMCP Editor-in-Chief Laura E. Happe ... Laura E. Happe , PharmD, MPH. --> ...
(Date:2/12/2016)... , February 12, 2016 /PRNewswire/ ... nicht anders vermerkt)   http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... des Unternehmens http://www.telestatherapeutics.com abrufbar.    ... (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss des ...
(Date:2/12/2016)... VIEJO, Calif. , Feb. 12, 2016  Sequent ... enrollment in a study to evaluate the safety and ... for the treatment of ruptured intracranial aneurysms.  Prof ... University Hospital, in Paris, France ... first patient. France and ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... Good news ... first in the area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, imaging ... as macular degeneration, diabetic retinopathy, and other vascular conditions. , In just a ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... With FCPX ... overlays to footage all within Final Cut Pro X. Each user can select from ... 3D rotation, angle of view, blur, focus offset, hue, saturation, value, contrast, glow, and ...
(Date:2/13/2016)... ... ... In the early or “honeymoon” stage of a relationship, couples strive to ... way to be romantic, and may exaggerate a strength or two in an effort ... , A recent study from Queendom.com , however, suggests that new couples ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to ... students from U.S. universities who will draw from Siemens’ deep knowledge of ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal Rabinowitz ... no time to decompress, Rabinowitz found herself drawn to a casual meditation class while ... on her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure ...
Breaking Medicine News(10 mins):